Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Revenio Group

27.4

 

EUR

 

-1.79 %

14,057 following

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more
Market cap
731.06M EUR
Turnover
371.75K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Accumulate
Target price
Updated
30.04.2025
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 30.04.2025

Latest extensive report

Released: 21.01.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
7.8.
2025

Interim report Q2'25

30.10.
2025

Interim report Q3'25

Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Regulatory press release5/15/2025, 6:00 AM

Revenio Group Corporation’s Board of Directors resolved on the long-term incentive plan’s performance period 2025–2027

Revenio Group
Regulatory press release5/14/2025, 1:00 PM

Revenio Group Corporation: Managers' Transactions – Anat Loewenstein

Revenio Group
Regulatory press release5/14/2025, 1:00 PM

Revenio Group Corporation: Managers' Transactions – Riad Sherif

Revenio Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release5/14/2025, 1:00 PM

Revenio Group Corporation: Managers' Transactions – Heli Lindfors

Revenio Group
Regulatory press release5/14/2025, 1:00 PM

Revenio Group Corporation: Managers' Transactions – Bill Östman

Revenio Group
Regulatory press release5/14/2025, 1:00 PM

Revenio Group Corporation: Managers' Transactions – Ann-Christine Sundell

Revenio Group
Regulatory press release5/14/2025, 1:00 PM

Revenio Group Corporation: Managers' Transactions – Pekka Tammela

Revenio Group
Regulatory press release5/14/2025, 1:00 PM

Revenio Group Corporation: Transfer of the Company's own shares

Revenio Group
Regulatory press release5/14/2025, 1:00 PM

Revenio Group Corporation: Managers' Transactions – Arne Boye Nielsen

Revenio Group
Revenio Q1'25: Exemplary performance
Research4/30/2025, 11:54 AM by
Juha Kinnunen

Revenio Q1'25: Exemplary performance

Revenio's Q1 result operationally exceeded our expectations, both in terms of revenue growth and EBIT. The outlook remains unchanged and the trade war does not seem to cause the company greater problems, at least in the light of current information.

Revenio Group
Revenio Interim report 1-3/2025
Webcast4/29/2025, 12:00 PM

Revenio Interim report 1-3/2025

Revenio Group
Regulatory press release4/29/2025, 6:00 AM

Revenio Group Corporation: Interim report January 1- March 31, 2025

Revenio Group
Press release4/24/2025, 1:00 PM

Modular Finance IR Consensus: Revenio Group – Consensus estimates Q1 2025

Revenio Group
Revenio Q1'25 preview: Risks have increased significantly
Analyst Comment4/22/2025, 7:55 AM by
Juha Kinnunen

Revenio Q1'25 preview: Risks have increased significantly

Revenio will publish its Q1 report next Tuesday at around 9.00 am EEST. We expect revenue and EBIT to grow significantly in a seasonally weak first quarter.

Revenio Group
Press release4/17/2025, 6:00 AM

Invitation to Revenio Group’s audiocast and teleconference call

Revenio Group
Regulatory press release4/10/2025, 3:00 PM

Resolutions of Revenio Group Corporation's Annual General Meeting 2025 and the organizing meeting of the Board of Directors

Revenio Group
Regulatory press release4/10/2025, 12:30 PM

Change in the amount of Revenio Group Corporation’s treasury shares

Revenio Group
Analyst Comment4/4/2025, 1:23 PM by
Juha Kinnunen, Atte Riikola, Thomas Westerholm, Pauli Lohi, Rauli Juva, Aapeli Pursimo, Antti Viljakainen

Case: Potential impacts of U.S. import tariffs on Helsinki Stock Exchange companies

The new import duties announced by the United States are causing headaches for several companies on the Helsinki Stock Exchange, in addition to generally weakening the global economic outlook and increasing uncertainty. Under the current US administration, situations can change rapidly, but according to the current plan, the tariffs should come into effect next Wednesday. The indirect effects of the current trade policy, and especially a potentially looming full-blown trade war, are likely to be greater for most companies than the direct effects, but in this compilation, we outline the potential effects of US import duties on various companies and sectors. This is our best estimate of the current impact, but the situation is evolving and uncertainty is now very high.

OptomedRevenio GroupDetection TechnologyNokiaTelesteRapala VMCWärtsiläVaisalaFiskarsHarviaMetsoKalmarGlastonPonsseKoneKonecranesRobitValmetRauteMetsä BoardStora Enso
Analyst Comment3/28/2025, 9:27 AM by
Juha Kinnunen

Revenio: iCare MAIA microperimeter cleared for marketing in the US

As expected, the FDA cleared Revenio's new iCare MAIA microperimeter. Thus, the new iCare MAIA microperimeter is now available for sale in the US, with deliveries starting in mid-April 2025, according to the company.

Revenio Group
Press release3/28/2025, 7:00 AM

U.S. FDA cleared the new iCare MAIA microperimeter

Revenio Group
Forum discussions
Revenio herättää tällä hetkellä yllättävän vähän keskustelua, vaikka yhtiö on tällä hetkellä ainakin omasta mielestäni mielenkiintoisimmassa tilanteessa vuosikausiin. Ja yhtiötä saa samalla kurssitasolla kuin 5 vuotta sitten! Tuli katsottua ajan kanssa Revenion Q1-webcast ja Jouni...
5/9/2025, 10:03 AM
by MTES
42
Juha Kinnunen ehti aamulla jo haastattelemaan Revenion toimaria Jouni Toijalaa Inderes Revenio Q1'25: Vuosi käyntiin vakuuttavasti - Inderes Aika: 29.04.2025 klo 11.12 Revenion Q1-tulos oli vahva ja yhtiö saavutti ensimmäisen kvartaalin myynti- ja kannattavuusennätyksen. Lisäksi ...
4/29/2025, 11:01 AM
by Sijoittaja-alokas
24
Juha on tehnyt uuden yhtiöraportin Reveniosta. Toistamme Reveniolle lisää -suosituksen 30,0 euron tavoitehinnalla. Q1-tulos ylitti operatiivisesti odotuksemme niin liikevaihdon kasvun kuin liiketuloksenkin osalta. Näkymä oli ennallaan eikä kauppasota vaikuta aiheuttavan suurempia...
4/30/2025, 8:06 AM
by Sijoittaja-alokas
13
RBC Capital - joka 11.4 laski tavoitehinnan 28,0 euroon, kommentoi positiivisesti että FY2025 tulosriskit pienenivät 1Q2025 tuloksen myötä, ja myös tariffikommentit olivat hyvä juttu. Tulosohjeistus kuitenkin lavea, ja konsespäivityksissä muuta prosenttiyksikön päivitysmahdollisuus...
4/29/2025, 9:39 AM
by Opa
13
Tämäkin sopii hyvin tänne Revenion ketjuun. @Sheikki linkitti Optomedin ketjuun @Sheikki Optomed Aurorallla tehty vertailututkimus RetCAD ja OphtAI -algoritmeilla, n=150. Hyvin näyttää Aurora toimivan, ainakin (Icaren/Revenion nykyään omistaman) Retcadin kanssa. … Automated diabetic...
5/24/2025, 5:15 PM
by BossoB
10
Onkohan tästä tällä jo mainittu? Alan kärkilehdessä kotimittauksen luotettavuutta vahvistettu tuoreella tutkimuksella, vertailussa Goldman, IC200 ja potilaan oma mittaus kotimittarilla. Tulokset perin myönteisiä. Edelleen puuttuu sellainen tutkimus jossa kotimittauksien käytöllä ...
6/1/2025, 9:14 AM
by veronmaksaja
7
Riskiä omasta mielestä poisti kommentit että tulleihin on varauduttu ja usa:n varastoissa on 2-6kk edestä tavaraa(näinkö se sanoi?) Olen samaa mieltä että Maia tuo y/y kasvulle hyvät luvut q2 raportissa ja sama jatkuu varmasti vuoden loppuun. Samalla olen odottanut miten tekoäly ...
5/9/2025, 4:28 PM
by Kari
4
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.